Yoshiyuki Aikawa Sells 3,100,000 Shares of SBC Medical Group (NASDAQ:SBC) Stock

SBC Medical Group Holdings Incorporated (NASDAQ:SBC) CEO Yoshiyuki Aikawa sold 3,100,000 shares of the firm’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $3.02, for a total value of $9,362,000.00. Following the transaction, the chief executive officer owned 79,304,460 shares of the company’s stock, valued at $239,499,469.20. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Yoshiyuki Aikawa also recently made the following trade(s):

• On Friday, March 6th, Yoshiyuki Aikawa sold 4,422,900 shares of SBC Medical Group stock. The stock was sold at an average price of $2.12, for a total value of $9,376,548.00.

SBC Medical Group Stock Performance

Shares of SBC remained flat at $3.40 during trading hours on Thursday. The stock had a trading volume of 140,319 shares, compared to its average volume of 117,629. The company’s 50-day moving average is $4.01 and its two-hundred day moving average is $4.02. The company has a quick ratio of 3.74, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $348.77 million, a PE ratio of 6.94 and a beta of 0.99. SBC Medical Group Holdings Incorporated has a 12-month low of $2.97 and a 12-month high of $5.75.

SBC Medical Group (NASDAQ:SBC) last posted its quarterly earnings results on Friday, March 27th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. The firm had revenue of $39.57 million during the quarter, compared to analyst estimates of $45.19 million. SBC Medical Group had a return on equity of 20.76% and a net margin of 29.37%. Research analysts anticipate that SBC Medical Group Holdings Incorporated will post 0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SBC Medical Group

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. bought a new stake in SBC Medical Group in the 4th quarter worth about $49,000. Russell Investments Group Ltd. increased its holdings in SBC Medical Group by 292.0% in the 4th quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock worth $51,000 after buying an additional 8,771 shares in the last quarter. Nuveen LLC bought a new stake in SBC Medical Group in the 4th quarter worth about $53,000. Wells Fargo & Company MN increased its holdings in SBC Medical Group by 195.1% in the 4th quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock worth $54,000 after buying an additional 8,348 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in SBC Medical Group in the 2nd quarter worth about $64,000. 60.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on SBC. BTIG Research began coverage on SBC Medical Group in a research report on Friday, March 6th. They issued a “buy” rating and a $8.00 price target for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of SBC Medical Group in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.50.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.